

Supplementary Appendix

Li E, Schroader BK, Campbell D, Campbell K, Wang W. The impact of baseline risk factors on the incidence of febrile neutropenia in breast cancer patients receiving chemotherapy with pegfilgrastim prophylaxis: a real-world data analysis. *JHEOR*. 2021;8(1):106-115. [doi:10.36469/jheor.2021.24564](https://doi.org/10.36469/jheor.2021.24564)

Table S1. Regimen Risk

This supplementary material has been provided by the authors to give readers additional information about their work.



Regimen Risk Level	Regimens Included
High Risk	Cyclophosphamide, epirubicin every <20 days Docetaxel, cyclophosphamide (TC) Docetaxel, carboplatin, trastuzumab (TCH) Docetaxel, carboplatin, trastuzumab, pertuzumab Docetaxel, doxorubicin, cyclophosphamide (TAC) Doxorubicin, cyclophosphamide (AC) every <20 days Fluorouracil, epirubicin, cyclophosphamide Gemcitabine, carboplatin Methotrexate, cyclophosphamide, fluorouracil every <20 days Paclitaxel, carboplatin, trastuzumab Paclitaxel, carboplatin, trastuzumab, pertuzumab Paclitaxel every <20 days Trastuzumab, methotrexate, fluorouracil, cyclophosphamide every <20 days
Intermediate Risk	Carboplatin, etoposide Carboplatin, docetaxel Carboplatin, paclitaxel Cyclophosphamide, epirubicin every 21 days Cyclophosphamide, methotrexate Docetaxel Docetaxel, carboplatin, pertuzumab Docetaxel, trastuzumab Docetaxel, trastuzumab, pertuzumab Doxorubicin, cyclophosphamide (AC) for 1 cycle or every 21+ days Methotrexate, cyclophosphamide, fluorouracil every 21+ days Paclitaxel every 21+ days Paclitaxel, trastuzumab, pertuzumab
Other	Any regimen not defined as high- or intermediate-risk regimens